Oppenheimer lowered the firm’s price target on Crescent Capital BDC (CCAP) to $19 from $20 and keeps an Outperform rating on the shares following quarterly results. The firm says its estimate changes reflect Q3 actuals and updated guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP:
- Crescent Capital BDC price target lowered to $15.50 from $17 at Keefe Bruyette
- Crescent Capital BDC price target lowered to $14 from $15 at Wells Fargo
- Crescent Capital BDC Reports Q3 2025 Earnings
- Crescent Capital BDC, Inc. Earnings Call Insights
- Crescent Capital BDC price target lowered to $15.50 from $16.50 at Clear Street